Payment overview · 2025
General Payments
$1,478.98
74 reported records · 19 companies
Healthcare provider profile · identity verified
Rainer A Khetan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DALLAS, TX · NPI 1225059256
Verified facts
What the public records show
CMS Open Payments records show Rainer A Khetan, M.D. received $1,478.98 in general payments during 2025 across 74 reported records.
Novartis Pharmaceuticals Corporation accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $242.13 | 16.4% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $211.41 | 14.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $188.87 | 12.8% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.33 | 7.3% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $101.80 | 6.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $91.26 | 6.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $86.64 | 5.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.49 | 5.0% | 4 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $61.55 | 4.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $59.66 | 4.0% | 4 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $49.62 | 3.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $42.39 | 2.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $41.91 | 2.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $29.73 | 2.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.47 | 1.5% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $20.64 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.87 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.61 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.60 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,478.98 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $242.13 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $117.79 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $101.80 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $98.34 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $98.34 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $93.62 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $93.62 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $93.62 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $90.53 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $86.64 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $81.51 | 4 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $61.55 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $61.55 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $59.66 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.74 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.68 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.40 | 2 | 2025 |
Source payment records
|
|||||
| BALFAXAR Normalized: balfaxar |
Biological | Octapharma USA, Inc. | $49.62 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $42.39 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $29.73 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 30 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 161 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 47 |
| Losartan Potassium | Losartan Potassium | 144 | 44 |
| Gabapentin | Gabapentin | 117 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 109 | 30 |
| Simvastatin | Simvastatin | 108 | 31 |
| Eliquis | Apixaban | 100 | 24 |
| Ezetimibe | Ezetimibe | 93 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 30 |
| Lisinopril | Lisinopril | 85 | 24 |
| Prednisone | Prednisone | 83 | 56 |
| Mounjaro | Tirzepatide | 82 | 12 |
| Metformin Hcl | Metformin Hcl | 78 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 23 |
| Meloxicam | Meloxicam | 68 | 17 |
| Omeprazole | Omeprazole | 68 | 22 |
| Azithromycin | Azithromycin | 65 | 50 |
| Furosemide | Furosemide | 65 | 23 |
| Allopurinol | Allopurinol | 62 | 17 |
| Clonazepam | Clonazepam | 62 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 22 |
| Alprazolam | Alprazolam | 60 | 18 |
| Ozempic | Semaglutide | 59 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 19 |
| Celecoxib | Celecoxib | 53 | 16 |
| Donepezil Hcl | Donepezil Hcl | 53 | 15 |
| Valacyclovir | Valacyclovir Hcl | 53 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 17 |
| Trazodone Hcl | Trazodone Hcl | 49 | 19 |
| Montelukast Sodium | Montelukast Sodium | 47 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 28 |
| Methylprednisolone | Methylprednisolone | 44 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Ondansetron Odt | Ondansetron | 40 | 19 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 20 |
| Glipizide | Glipizide | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Tadalafil | Tadalafil | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 15 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | 12 |
| Finasteride | Finasteride | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Acetazolamide Er | Acetazolamide | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,478.98 · 74 records | Novartis Pharmaceuticals Corporation | ABRYSVO, AIRSUPRA, AREXVY, BALFAXAR, COMIRNATY, Cleerly Ischemia, Cleerly Labs, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GEMTESA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, LEQVIO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error